Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.6
(10.43%)
SEK 3.6
(10.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -20.79 Million SEK | 86.05% |
| 2022 | -149.07 Million SEK | 42.65% |
| 2021 | -259.94 Million SEK | -42.12% |
| 2020 | -182.9 Million SEK | -68.7% |
| 2019 | -108.42 Million SEK | 27.64% |
| 2018 | -149.82 Million SEK | -172.1% |
| 2017 | -55.06 Million SEK | -3284.33% |
| 2016 | -1.62 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -7.73 Million SEK | 62.78% |
| 2024 Q2 | 4.29 Million SEK | 155.49% |
| 2023 Q2 | -68.92 Million SEK | 37.09% |
| 2023 FY | -20.79 Million SEK | 86.05% |
| 2023 Q4 | -20.79 Million SEK | 44.88% |
| 2023 Q3 | -37.72 Million SEK | 45.27% |
| 2023 Q1 | -109.56 Million SEK | 26.5% |
| 2022 FY | -149.07 Million SEK | 42.65% |
| 2022 Q4 | -149.07 Million SEK | 16.76% |
| 2022 Q3 | -179.08 Million SEK | 13.89% |
| 2022 Q2 | -207.98 Million SEK | 10.14% |
| 2022 Q1 | -231.46 Million SEK | 10.96% |
| 2021 Q2 | -316.81 Million SEK | -93.37% |
| 2021 Q1 | -163.83 Million SEK | 10.43% |
| 2021 Q3 | -289.1 Million SEK | 8.75% |
| 2021 Q4 | -259.94 Million SEK | 10.09% |
| 2021 FY | -259.94 Million SEK | -42.12% |
| 2020 FY | -182.9 Million SEK | -68.7% |
| 2020 Q2 | -75.8 Million SEK | 25.28% |
| 2020 Q1 | -101.45 Million SEK | 6.43% |
| 2020 Q3 | -150.44 Million SEK | -98.47% |
| 2020 Q4 | -182.9 Million SEK | -21.58% |
| 2019 Q4 | -108.42 Million SEK | 16.41% |
| 2019 FY | -108.42 Million SEK | 27.64% |
| 2019 Q2 | -149.82 Million SEK | 31.63% |
| 2019 Q1 | -219.14 Million SEK | -420.4% |
| 2019 Q3 | -129.69 Million SEK | 13.43% |
| 2018 Q2 | -55.06 Million SEK | 0.0% |
| 2018 Q4 | -42.11 Million SEK | 0.0% |
| 2018 FY | -149.82 Million SEK | -172.1% |
| 2017 FY | -55.06 Million SEK | -3284.33% |
| 2016 FY | -1.62 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 37.37% |
| Biovica International AB (publ) | -58.73 Million SEK | 64.6% |
| Cantargia AB (publ) | -139.74 Million SEK | 85.121% |
| CombiGene AB (publ) | -101.44 Million SEK | 79.502% |
| Cyxone AB (publ) | -16.67 Million SEK | -24.733% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -599.63% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 29.235% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 62.794% |
| Fluicell AB (publ) | -2.76 Million SEK | -652.552% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 93.681% |
| Mendus AB (publ) | -96.29 Million SEK | 78.407% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 84.949% |
| I-Tech AB | -83.26 Million SEK | 75.027% |
| Intervacc AB (publ) | -88.16 Million SEK | 76.414% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 34.873% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 139.068% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -9.092% |
| OncoZenge AB (publ) | -12.62 Million SEK | -64.671% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 58.359% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 112.52% |
| Lipum AB (publ) | -8.46 Million SEK | -145.635% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 58.431% |
| Ziccum AB (publ) | -2.13 Million SEK | -873.0% |
| BioArctic AB (publ) | -606.58 Million SEK | 96.572% |
| Genovis AB (publ.) | -43.94 Million SEK | 52.68% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.216% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 75.17% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 47.202% |
| Aptahem AB (publ) | 2.9 Million SEK | 814.87% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 93.767% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 83.943% |
| Kancera AB (publ) | -45.69 Million SEK | 54.493% |
| Saniona AB (publ) | 40.44 Million SEK | 151.408% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 54.015% |
| AcouSort AB (publ) | -23.98 Million SEK | 13.312% |
| Xintela AB (publ) | -7.8 Million SEK | -166.27% |
| Abliva AB (publ) | -57.24 Million SEK | 63.674% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 74.705% |
| Amniotics AB (publ) | -5.63 Million SEK | -269.194% |
| 2cureX AB (publ) | -13.4 Million SEK | -55.137% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -862.193% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 485.056% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 115.436% |
| Biosergen AB | -1.88 Million SEK | -1004.249% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 201.38% |
| Corline Biomedical AB | -17.01 Million SEK | -22.225% |
| NextCell Pharma AB | -46.79 Million SEK | 55.562% |
| Nanologica AB (publ) | -9.38 Million SEK | -121.485% |
| LIDDS AB (publ) | -13.51 Million SEK | -53.885% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 89.32% |
| BioInvent International AB (publ) | -236.3 Million SEK | 91.201% |
| SynAct Pharma AB | -61.75 Million SEK | 66.331% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 2.905% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -57.175% |
| Alzinova AB (publ) | -21.22 Million SEK | 2.04% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 68.929% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -301.338% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 75.17% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -2152.763% |
| Simris Alg AB (publ) | 85.07 Million SEK | 124.441% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 74.669% |